Research Article

A study of coagulation profile in patients with cancer in a tertiary care hospital

Gaurav Khichariya, Manjula K*, Subhashish Das and Kalyani R

Published: 10 February, 2021 | Volume 5 - Issue 1 | Pages: 001-003

The complicated process of cancer triggers many physiological systems like vascular endothelial functions and hemostasis, which signifies the increased risk of thrombosis, which triggers thromboembolic events resulting in increased mortality and morbidity [1-3]. Tumorigenesis contributes by activation of coagulation around the perivascular region [4].

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001015 Cite this Article Read Full Article PDF


  1. Mirshahi S, Pritchard LL, Pocard M, Mirshahi M, Soria J. Pathogenesis and Diagnosis of Venous Hypercoagulable States in Cancer. J Hematol Thrombo Dis. 2015; 3: 3.
  2. Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N et al. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol. 2011; 22: 2394-2402. PubMed: https://pubmed.ncbi.nlm.nih.gov/21393379/
  3. Kirwan CC, McDowell G, McCollum CN, Byrne GJ. Incidence of Venous Thromboembolism during Chemotherapy for Breast Cancer: Impact on Cancer Outcome. Anticnacer Res. 2011; 31: 2383-2388. PubMed: https://pubmed.ncbi.nlm.nih.gov/21737669/
  4. Bremnes RM, Donnem T, Al-Saad S, Camps C, Marinez I, et al. The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer. J Thorac Oncol. 2011; 6: 209-217. PubMed: https://pubmed.ncbi.nlm.nih.gov/21107292/
  5. Dvorak HF. Thrombosis and cancer. Hum Pathol. 1987; 18: 275–284.
  6. Tempelhoff GFV, Heilmann L, Hommel G, Pollow K. Impact of Rheological variables in Cancer. Seminars in Thrombosis and Hemostasis. 2003; 29: 499-513. PubMed: https://pubmed.ncbi.nlm.nih.gov/14631550/
  7. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000; 83: 164–170. PubMed: https://pubmed.ncbi.nlm.nih.gov/10901365/
  8. Caine GJ, Stonelake PS, Rea D, Lip GYH. Coagulopathic Complications in Breast Cancer. Cancer. 2003; 98: 1578-186. PubMed: https://pubmed.ncbi.nlm.nih.gov/14534872/
  9. Bleker SM, Van Es N, Van Gills L, Daams JG, Kleinjan A, et al. Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review. Thrombo Res. 2016; 140: S81-S88. PubMed: https://pubmed.ncbi.nlm.nih.gov/27067985/
  10. Tas F, Kilic L, Duranyildiz D. Coagulation tests show significant differences in patients with breast cancer. Tumor Biol. 2014; 35: 5985-5992. PubMed: https://pubmed.ncbi.nlm.nih.gov/24596033/
  11. Prandoni P, Cornwali M, Marchiori A. Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparinin the Initial Treatment of Venous Thromboembolism. Arch Interna Med. 2004; 164: 1077-1083. PubMed: https://pubmed.ncbi.nlm.nih.gov/15159264/
  12. Wang Hui, Xu X, Pu C, Li L. Clinical characteristics and prognosis of cancer patients with venous thromboembolism. J Cancer Res Therapeut. 2019; 15: 344-349. PubMed: https://pubmed.ncbi.nlm.nih.gov/30964109/
  13. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost. 2007; 33: 688-694. PubMed: https://pubmed.ncbi.nlm.nih.gov/18000796/
  14. Beleva E, Popov V, Popova JG. Hemostatic System in Malignancy: Providing the “Soil” in Metastatic Niche Formation, Tumor Metastasis, Ke Xu, IntechOpen. 2016. https://www.intechopen.com/books/tumor-metastasis/hemostatic-system-in-malignancy-providing-the-soil-in-metastatic-niche-formation
  15. Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the hemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer. 2008; 99: 1000–1006. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567096/
  16. Batschauer APB, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LMS, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010; 21: 1267–272. PubMed: https://pubmed.ncbi.nlm.nih.gov/19880435/

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More